Introduction to ELIXIR Andy Smith, ELIXIR Hub 18 March 2015 Wageningen
|
|
- Hope Bishop
- 6 years ago
- Views:
Transcription
1 Introduction to ELIXIR Andy Smith, ELIXIR Hub 18 March 2015 Wageningen European Life Sciences Infrastructure for Biological Information europe.org
2 ELIXIR connects national bioinformatics centres and EMBL EBI into a sustainable European infrastructure for biological research data medicine agriculture 2 environment bioindustries ELIXIR underpins life science research across academia and industry
3 The data challenge: Volume Gigabytes N Databases
4 The data challenge: Geographically disperse Data production sites increasing across Europe European Illumina sales up 20% 2o14 Source: 4
5 The data challenge: diversity databases Diverse Plentiful Disperse Nucleic Acids Research annual Database Issue and the NAR online Molecular Biology Database Collection in MY Galperin, GR Cochrane Nucleic Acids Research, 2011
6 An international distributed infrastructure for Data Standards Tools Compute Training Industry
7 A distributed infrastructure scales with the challenges ELIXIR deliver services through national ELIXIR Nodes ELIXIR Nodes build local bioinformatics capacity throughout Europe ELIXIR Nodes build on national strengths and priorities 7
8 ELIXIR funding Hub funded jointly by ELIXIR member states Nodes funded by national agencies Joint applications to EU funding
9 ELIXIR Nodes Over 100 institutes involved in ELIXIR Nodes Collaboration Agreements to be signed between Hub and Nodes Nodes that are national networks are developing own internal Node agreements 9
10 ELIXIR Core Data Resources Small subset of ELIXIR data resources and archives Fundamental importance to life science Long term preservation and reuse of biological data Focal point of ELIXIR s technical and science policy actions for data sustainability
11 ELIXIR Named Services Quality indicator of the Service or Tool have clearly outlined terms of usage, declared service levels and monitoring vetted by the ELIXIR SAB as part of Node application Sustainability & Commitment to Service Described in Service Delivery Plans annexed to the Hub Node Collaboration Agreements
12 ELIXIR tools and data registry
13 Integration and interoperability of resources typically 40% of our effort in biomarker discovery is data integration J. Wojcik, CEO, Quartz Bio Formats, Ontologies, Guidelines, 13 Professional skills for managing and exploiting data
14 Data interoperability Human Protein Atlas The Human Protein Atlas portal is a publicly available database with millions of high-resolution images showing the spatial distribution of proteins in 46 different normal human tissues and 20 different cancer types, as well as 47 different human cell lines.
15 ELIXIR pilots to address key challenges in biomedical research: 1. Cloud computing Embassy cloud : Access reference data in a virtual environment work as though you are at EMBL-EBI or SIB, Switzerland 2. Authentication & Authorisation Improved methods and processes for access to clinical data 3. High-Performance Computing Lightpath : Connections for on-demand reference data to remote HPC centres at EMBL-EBI and CSC Finland
16 ELIXIR prioritised by ESFRI and Council of EU
17 ELIXIR EXCELERATE ELIXIR s application following ESFRI Prioritisation in 2014 Results expected in Spring; project start Summer Eur 19 million 4 year project Focus on accelerating the implementation of ELIXIR Use case on Plant Sciences: Integrating Genomic and Phenotypic Data for Crop and Forest Plants
18 ELIXIR Industry Advisory Committee Philippe Sanseau, GlaxoSmithKline, UK Wendy Filsell, Unilever R&D, UK (Vice Chair) Angel Pizarro, Amazon Web Services, USA Jakob de Vlieg, Bayer CropSciences Innovation Center, Belgium Martin Ebeling, Hoffmann La Roche, Switzerland Anita Eliasson, Biocomputing Platforms Ltd, Finland Mark Forster, Syngenta, UK (Chair) Montserrat Vendrell, Biocat, Spain Natalia Jiménez Lozano, Bull and Atos, Spain Iain Hrynaszkiewicz, Nature Publishing Group Macmillan, UK Claus Stie Kallesøe, Gritsystems A/S, Denmark 18
19 Industry Advisory Committee
20 Public data: a foundation for innovation Supporting Europe s SMEs that build services on top of the public bioinformatics resources understanding impact ELIXIR Core Resources and Named Services Facilitating integration through Pilot Actions
21 Innovation and SME programme Copenhagen, November 2014 Focussed on pharma and ELIXIR resources for drug discovery Wageningen, March 2015 Data driven growth in the agri food industries Basel, 9 June 2015 Pharma and biotech Future events? Marine informatics HPC suppliers
22 Benefit of ELIXIR to industry supplier The life science sector as a consumer of HPC is already high and set to increase further 22
23 ELIXIR industry distribution channel Mailing list of around 200 companies and SME Associations Events, news and industry/academia funding opportunities from across ELIXIR Content, reach and frequency to expand through 2015
24 ELIXIR webinars Regular series of updates from ELIXIR Typically 3 rd Wednesday of month 30 minute talk: 30 min questions Future webinars: Data and Software carpentry Aleksandra Pawlik Marine metagenimics: towards user centric services Nils Peder Willassen Run using WebEx for live or recorded viewing Full programme: elixir europe.org/webinar 24
25 Thank you europe.org
ELIXIR connects national centres and EMBL EBI to build a sustainable European infrastructure for biological research data. medicine.
ELIXIR connects national centres and EMBL EBI to build a sustainable European infrastructure for biological research data. medicine agriculture 1 environment bioindustries ELIXIR underpins life science
More informationTools, techniques and infrastructure bioinformatics in marine biotechnology
Tools, techniques and infrastructure bioinformatics in marine biotechnology Second Marine Biotechnology ERA-NET Stakeholder Meeting 13 th - 14 th October 2016, Hotel Marivaux, Brussels, Belgium Nils Peder
More informationELIXIR: data for molecular biology and points of entry for marine scientists
ELIXIR: data for molecular biology and points of entry for marine scientists Guy Cochrane, EMBL-EBI EuroMarine 2018 General Assembly meeting 17-18 January 2018 www.elixir-europe.org Scales of molecular
More informationInterpreting Genome Data for Personalised Medicine. Professor Dame Janet Thornton EMBL-EBI
Interpreting Genome Data for Personalised Medicine Professor Dame Janet Thornton EMBL-EBI Deciphering a genome 3 billion bases 4 million variants 21,000 coding variants 10,000 non-synonymous variants 50-100
More informationElixir: European Bioinformatics Research Infrastructure. Rolf Apweiler
Elixir: European Bioinformatics Research Infrastructure Rolf Apweiler EMBL-EBI Service Mission To enable life science research and its translation to medicine, agriculture, the bioindustries and society
More informationELIXIR KPI framework and alignment of KPIs between e-infrastructures and research infrastructures
ELIXIR KPI framework and alignment of KPIs between e-infrastructures and research infrastructures Rafael C Jimenez, ELIXIR CTO June 8, 2017 e-irg workshop June 2017 www.elixir-europe.org ELIXIR European
More informationEuropean Genome phenome Archive at the European Bioinformatics Institute. Helen Parkinson Head of Molecular Archives
European Genome phenome Archive at the European Bioinformatics Institute Helen Parkinson Head of Molecular Archives What is EMBL-EBI? International, non-profit research institute Part of the European Molecular
More informationELIXIR Service portfolio management
ELIXIR Service portfolio management ELIXIR Types of services Governance structure Portfolio management Compliant services? Rafael C Jimenez, CTO EOSC stakeholder forum Nov 29, 2017 www.elixir-europe.org
More informationA framework for quality management in the biomedical research infrastructures (BMS RIs)
Common BMS RI Framework for Quality Management A framework for quality management in the biomedical research infrastructures (BMS RIs) BMS RIs put quality at the heart of biomedical research It has been
More informationWP4: Data services and reporting standards
WP4: Data services and reporting standards WP leader Guy Cochrane EMBL-EBI WP co-leader Nils-Peder Willassen UiT Task 4.1 leader Jeena Rajan EMBL-EBI Task 4.2 leader Jeena Rajan EMBL-EBI Task 4.3 leader
More informationWP2 Legal, Governance & Ethical Issues
WP2 Legal, Governance & Ethical Issues Stakeholder Meeting in Heidelberg 30 January 2012 Co- Chairs Dr. Edvard Beem, ZonMW, NL Dr. Silke Schumacher, EMBL WP2 Deliverables Deliverables by January 2012:
More informationVon Mäusen und Menschen Datenbrücken verbessern den Zugang zu Forschungsdaten in INFRAFRONTIER
Von Mäusen und Menschen Datenbrücken verbessern den Zugang zu Forschungsdaten in INFRAFRONTIER Michael Raess & Philipp Gormanns, Helmholtz Zentrum München Helmholtz Open Access Webinars 16 and 24 July
More informationProfessor Ewan Birney FRS Director, EMBL-EBI
Infrastructures for research and innovation Professor Ewan Birney FRS Director, EMBL-EBI www.ebi.ac.uk Outline of talk Who Am I, What is EMBL? The change in genomics The needs for stratified patients in
More informationINNOVATIVE CONCEPTS ON DATA GENERATION AND USE FOR PERSONALISED MEDICINE RESEARCH
Data collection and Management in PM Research Alfonso Valencia ICREA Research Professor Director, Life Sciences Department BSC Director, Spanish National Bioinformatics Institute (INB-ISCIII) Head of the
More informationAccess to Information from Molecular Biology and Genome Research
Future Needs for Research Infrastructures in Biomedical Sciences Access to Information from Molecular Biology and Genome Research DG Research: Brussels March 2005 User Community for this information is
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More informationThe EMBL-Bioinformatics and Data-Intensive Informatics
The EMBL-Bioinformatics and Data-Intensive Informatics Graham Cameron EMBL-EBI What is the EMBL-EBI? Non-profit organization Part of the European Molecular Biology Laboratory Based on the Wellcome Trust
More informationEESI Final Conference
FP7 Support Action - European Exascale Software Initiative DG Information Society and the unit e-infrastructures EESI Final Conference EESI WG3.4: Life Sciences and Health Modesto Orozco, Chair Janet Thornton,
More informationComputational Challenges in Life Sciences Research Infrastructures
Computational Challenges in Life Sciences Research Infrastructures Alvis Brazma European Bioinformatics Institute European Molecular Biology Laboratory European Bioinformatics Institute (EBI) EBI is in
More informationNordic Register and Biobank Data
Nordic Register and Biobank Data A basis for innovative research on health and welfare Juni Palmgren Karolinska Institutet, Stockholm Nordic conference on Real World Data Helsinki November 2016 Nordic
More informationEuropean Molecular Biology Laboratory
European Molecular Biology Laboratory Laboratoire Européen de Biologie Moléculaire Europäisches Laboratorium für Molekularbiologie Prof. Iain W. Mattaj, Director General EMBL Member States Austria 1974
More informationEMBL-EBI Overview EMBL-EBI Overview
EMBL-EBI Overview Welcome Welcome to the European Bioinformatics Institute (EMBL-EBI), a global hub for big data in biology. We promote scientific progress by providing freely available data to the life-science
More informationCommercialising Genomic Research 1-3 October 2018
Course Programme Commercialising Genomic Research 1-3 October 2018 Wellcome Genome Campus Hinxton, Cambridge, UK Monday 1 October 2018 09:30-10:00 Registration with refreshments 10:00-10:30 Introduction
More informationSafeSciMET. European Modular Education and Training Programme in Safety Sciences for Medicines
SafeSciMET European Modular Education and Training Programme in Safety Sciences for Medicines What patients need What Europe needs Rapid exploitation of insights in disease mechanisms for introduction
More informationElixir: Overview, Progress and Futures
Elixir: Overview, Progress and Futures 20th Meeting of the EC-US Biotechnology Task Force Barcelona 3 June 2010 Andrew Lyall, ELIXIR Project Manager www.elixir-europe.org ELIXIR: a sustainable infrastructure
More informationOpen PHACTS: Semantic interoperability for drug discovery
Open PHACTS: Semantic interoperability for drug discovery ACS National Meeting, San Diego Herman van Vlijmen 16 Mar 2016 Judith Hinton Andrew, Rock Composite 22 Artwork from The Creative Center What is
More informationFuture of the Project. BioMedBridges 3rd Annual General Meeting 18 February 2015, Munich Janet Thornton
Future of the Project BioMedBridges 3rd Annual General Meeting 18 February 2015, Munich Janet Thornton What were goals of BioMedBridges? GOAL 1: To provide computational data and service bridges between
More informationGeneration of research tools to translate genomic discoveries into drug discovery projects. Nils Ostermann, Novartis
Generation of research tools to translate genomic discoveries into drug discovery projects Nils Ostermann, Novartis Need for public-private collaboration Common interest Genomic information is growing
More informationELIXIR-GREECE Babis Savakis ELIXIR-GREECE kick-off meeting NHRF, Athens 18 May 2018
ELIXIR-GREECE Babis Savakis ELIXIR-GREECE kick-off meeting NHRF, Athens 18 May 2018 www.elixir-greece.org ELIXIR Membership ELIXIR-Greece CERTH U. of Thessaloniki U. of Ioannina Thessaloniki Alexandroupolis
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationKPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
More informationThe Open Pharmacological Concepts Triple Store
The Open Pharmacological Concepts Triple Store Gerhard F. Ecker Dept Medicinal Chemistry, Univ Vienna Gerhard.f.ecker@univie.ac.at; www.openphacts.org The Innovative Medicines Initiative EC funded public-private
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationELIXIR DK. Danish National Supercomputer for Life Sciences. European Life Sciences Infrastructure for Biological Information europe.
ELIXIR DK Danish National Supercomputer for Life Sciences European Life Sciences Infrastructure for Biological Information www.elixir europe.org National need for life science supercomputer Approx. 2%
More informationWebinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
More informationBiomarker discovery. Enabling pharmaceutical and biotech partners to discover relevant biomarkers in diseases of interest
Biomarker discovery Enabling pharmaceutical and biotech partners to discover relevant biomarkers in diseases of interest Biomarker discovery A biomarker is a measurable indicator of the severity or presence
More informationM a x i m i z in g Value from NGS Analytics in t h e E n terprise
Global Headquarters: 5 Speen Street Framingham, MA 01701 USA P.508.935.4445 F.508.988.7881 www.idc-hi.com M a x i m i z in g Value from NGS Analytics in t h e E n terprise C U S T O M I N D U S T R Y B
More informationTECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298
DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES March 2017. March 2017 ABA 298 1 Technologies, Products & Services
More informationDr. Thibaud Mascart. ERA-MBT final conference Oceans of opportunities. Oslo, 20 Nov 2017
Dr. Thibaud Mascart ERA-MBT final conference Oceans of opportunities Oslo, 20 Nov 2017 Enabling technologies and infrastructure there remains an acute need to continue to build research and innovation
More informationACCELERATING GENOMIC ANALYSIS ON THE CLOUD. Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes
ACCELERATING GENOMIC ANALYSIS ON THE CLOUD Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia
More informationEU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
More informationTRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University
TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS H a n n s Lochmüller, Newcastle University Addressing the translational pathway 2 Trials Gene identification/ pathophysiology
More informationHigh peformance computing infrastructure for bioinformatics
High peformance computing infrastructure for bioinformatics Scott Hazelhurst University of the Witwatersrand December 2009 What we need Skills, time What we need Skills, time Fast network Lots of storage
More informationGlobal Biomolecular Information Infrastructure and Australia. Graham Cameron Director The EMBL Australia Bioinformatics Resource
Global Biomolecular Information Infrastructure and Australia Graham Cameron Director The EMBL Australia Bioinformatics Resource What is bioinformatics? Methods, data, IT to exploit biomolecular information
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure
ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure Marialuisa Lavitrano Università Milano-Bicocca Coordinatore BBMRI-Italia
More informationThe European Bioinformatics Institute - Cambridge. Overview
The European Bioinformatics Institute - Cambridge Overview European Bioinformatics Institute (EMBL-EBI) Wellcome Genome Campus Hinxton, Cambridge CB10 1SD United Kingdom y www.ebi.ac.uk C +44 (0)1223 494
More informationBioXplain The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology
The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology BioXplain 2009 Pharma R&D critical challenge Despite increasing investments in Technology
More informationBioinformatics: Present & Future from an EBI Perspective. Janet Thornton. UCL February 14 th 2012
Bioinformatics: Present & Future from an EBI Perspective Janet Thornton UCL February 14 th 2012 What is bioinformatics? The science of storing, retrieving and analysing large amounts of biological information
More informationWebinar IMI2 Call 14 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
Webinar IMI2 Call 14 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery 16 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction
More informationOctober 6, Below we provide input from our community of health informatics experts regarding select portions of the Draft Guidance.
Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Submitted electronically via http://www.regulations.gov RE: Use of Public Human Genetic
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationOrphan Medicinal Products
Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000
More informationThe Innovative Medicines Initiative
The Innovative Medicines Initiative Innovative funding for biotechs & SMEs in Europe Pierre Meulien, IMI Executive Director BIO-Europe Conference, Copenhagen 06.11.2018 IMI Europe s partnership for health
More informationQ4. WORK STREAMS Discovery, Cloud, Large Scale Genomics. DRIVER PROJECTS ELIXIR Beacon, EVA/EGA/ENA. WORK STREAMS Discovery
2018 - Q4 Search The GA4GH Search API enables a search engine for genomic and clinical data by providing specification for query language across genomic, phenotypic, and clinical data that can be used
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationEMMA - European Mouse Mutant Archive Michael Hagn
EMMA - European Mouse Mutant Archive Michael Hagn EMMA - European Mouse Mutant Archive OVERVIEW EMMA objectives EMMA network EMMA archive statistics EMMA projects Infrafrontier Key Objectives of EMMA Archiving
More informationWelcome to the Ministry of Foreign Affairs
Welcome to the Ministry of Foreign Affairs indk@um.dk www.investindk.com National Experimental Therapy Partnership (NEXT) NEXT is a public-private partnership within clinical research offering a one stop
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationIRDiRC: International Rare Diseases Research Consortium
IRDiRC: International Rare Diseases Research Consortium EuRenomics, NEUROMICS and RD-Connect Joint Kick-off Meeting Sitges, Spain, 25 January 2013 Dr. Iiro Eerola Scientific Project Officer Unit for Personalised
More informationWhat has Open PHACTS done so far? Lee Harland On behalf of the Open PHACTS Consortium
What has Open PHACTS done so far? Lee Harland On behalf of the Open PHACTS Consortium Pre-competitive Informatics: Pharma are all accessing, processing, storing & re-processing external research data Literature
More informationPresent and Future ehealth Research Activities supported by DG INFSO. Gérard Comyn,
Present and Future ehealth Research Activities supported by DG INFSO Gérard Comyn, Head of Unit, ICT for Health, European Commission gerard.comyn@cec.eu.int Some facts Health care expenditure worldwide
More informationIntroduction to BIOINFORMATICS
Introduction to BIOINFORMATICS Antonella Lisa CABGen Centro di Analisi Bioinformatica per la Genomica Tel. 0382-546361 E-mail: lisa@igm.cnr.it http://www.igm.cnr.it/pagine-personali/lisa-antonella/ What
More informationBioXplain The Alliance for Integrative Biology
The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology Manuel GEA Co-founder & CEO Bio-Modeling Systems BioXplain 2009 Pharma R&D critical challenge
More informationDevelopments in BioPharma Grid Computing. Rowan Gardner, BioLauncher Ltd
Developments in BioPharma Grid Computing Rowan Gardner, BioLauncher Ltd PharmaGRID 2004 60 Delegates, a beautiful location, good food and excellent speakers Speakers Prof. Denis Noble, Applications in
More informationIntroduction to EMBL-EBI.
Introduction to EMBL-EBI www.ebi.ac.uk What is EMBL-EBI? Part of EMBL Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, the Netherlands,
More informationDrug Discovery insights. Building
DDin Drug Discovery insights Building Bridges TO ACCELERATE DRUG DISCOVERY The Valley of death Basic Research Applied Research Technology Development & Demonstration Product Commercialization & Market
More informationA European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
More informationEIB Support in Life Sciences. Shiva Dustdar Head of Division, Innovation Finance Advisory European Investment Bank BIO-Europe Berlin, 7 November 2017
EIB Support in Life Sciences Shiva Dustdar Head of Division, Innovation Finance Advisory European Investment Bank BIO-Europe Berlin, 7 November 2017 EIB at a glance The EU bank: Established in 1958 Shareholders
More informationMediSapiens Ltd. Because data is not knowledge. 4th of November Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd
4th of November 2014 MediSapiens Ltd Because data is not knowledge Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2014 MediSapiens Ltd. All rights reserved. medisapiens.com MediSapiens Brief
More informationBiobanking and Biomolecular Resources Research Infrastructure: The need for common standards
Biobanking and Biomolecular Resources Research Infrastructure: The need for common standards K. Zatloukal Medical University of Graz, Austria Washington, Embassy of Austria June 5th 2012 Biobanks and Biomolecular
More informationNetwork-centric Biomedicine: re-engineering the Knowledge Enterprise
Network-centric Biomedicine: re-engineering the Knowledge Enterprise Ken Buetow, Ph.D. Director Computational Science and Informatics Core Program, Complex Adaptive Systems Initiative Arizona State University
More informationThe Need for Scientific. Data Annotation. Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences.
The Need for Scientific Data Annotation Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences alaw@us.ibm.com Cross disciplinary research approach requires organizations to address diverse needs
More informationECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT
More informationA regulatory update in a day for Small to Medium-sized Enterprises
TOPRA ANNUAL SYMPOSIUM STOCKHOLM, SWEDEN In partnership with the Swedish Medical Products Agency Time of transformation: Implementing international regulatory change A regulatory update in a day for Small
More informationBiomarkers as an emerging growth area in Denmark
Biomarkers as an emerging growth area in Denmark International Conference on Perspectives in Precision Medicine, Copenhagen March 1, 2018 Kim Holmstrøm, PhD. Chairman of The Danish Biomarker Network R&D
More informationSynthetic Biology and Patents
Synthetic Biology and Patents Dr. Berthold Rutz, Directorate 2.4.01 Biotechnology European Patent Office Munich "Patenting Synthetic Biology? A Transatlantic Perspective" WWICS, Washington D.C. 30.11.2009
More informationOverview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017
FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures
More informationEBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
More informationSPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium
SPECTArare as an innovative model of combining clinical research and care in an ERN Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium Contents The changing clinical research pathway How
More informationEATRIS accelerates translation of science into medical products that benefit patients and improve human health.
OUR PURPOSE EATRIS is a permanent EU biomedical research infrastructure. EATRIS accelerates translation of science into medical products that benefit patients and improve human health. OUR AIMS 1. Improving
More informationBionure as a success case in the FP7. September, 2012
Bionure as a success case in the FP7 September, 2012 Company Bionure is a biotech company that focuses its efforts on the development of new therapies and diagnostic tools for neurological diseases, in
More informationEuropean bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013
European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013 Contents Who we are Our goals Our activities Wha we can offer
More informationWeek 1: Discovery Biology Basic knowledge and tools used in Research and Development
Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges
More informationPlanning a national bioinformatics infrastructure investment
Planning a national bioinformatics infrastructure investment 1 Infrastructure? 2 Research infrastructure? 3 Research infrastructure? 4 What is Bioinformatics Infrastructure? What is Bioinformatics Infrastructure?
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationData representation for clinical data and metadata
Data representation for clinical data and metadata WP1: Data representation for clinical data and metadata Inconsistent terminology creates barriers to identifying common clinical entities in disparate
More informationThe EORTC Molecular Screening programme SPECTA
The EORTC Molecular Screening programme SPECTA February 2016 Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium The changing shape of clinical research Phase I RESOURCES Phase III The changing
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationDuncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline
R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare
More informationOur website:
Biomedical Informatics Summer Internship Program (BMI SIP) The Department of Biomedical Informatics hosts an annual internship program each summer which provides high school, undergraduate, and graduate
More informationMRC Stratified Medicine Initiative
MRC Stratified Medicine Initiative Jonathan Pearce Medical Research Council, Translational Programme Manager Pharmacogenetics and Stratified Medicine Network Conference : 14 th January 2015 Stratified
More informationChemical education and the pharmaceutical industry*
Pure Appl. Chem., Vol. 71, No. 5, pp. 865±870, 1999. Printed in Great Britain. q 1999 IUPAC Chemical education and the pharmaceutical industry* Albert E. Fischli Pharmaceutical Research, F. Hoffmann-LaRoche
More informationEMBL-EBI and pan-national scale bioinformatics: Relevance to Australia
EMBL-EBI and pan-national scale bioinformatics: Relevance to Australia Paul Flicek Vertebrate Genomics, European Molecular Biology Laboratory Wellcome Trust Sanger Institute European Molecular Biology
More informationCOMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT. Accompanying the document. Proposal for a Council Regulation
EUROPEAN COMMISSION Brussels, 11.1.2018 SWD(2018) 6 final PART 3/4 COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT Accompanying the document Proposal for a Council Regulation on establishing the European
More informationThe High Performance Computing strategy and the European Cloud Initiative HPC User Forum September 5-7, 2017 Milwaukee, USA
The High Performance Computing strategy and the European Cloud Initiative HPC User Forum September 5-7, 2017 Milwaukee, USA Leonardo Flores Añover Senior Expert - HPC and Quantum technologies DG CONNECT
More informationBiomedical Informatics in BIG DATA Era
Biomedical Informatics in BIG DATA Era Yang C. Fann, Ph.D. Director, Intramural IT and Bioinformatics Program National Institute of Neurological Disorders and Stroke Disclaimer The opinions or assertions
More informationThe Innovate UK response to the Innovative Medicines Initiative consultation Facilitating the translation of advanced therapies to patients in Europe
The Innovate UK response to the Innovative Medicines Initiative consultation Facilitating the translation of advanced therapies to patients in Europe Innovate UK and ATMP background 1. Innovate UK is the
More informationBioinformatics and computational tools
Bioinformatics and computational tools Etienne P. de Villiers (PhD) International Livestock Research Institute Nairobi, Kenya International Livestock Research Institute Nairobi, Kenya ILRI works at the
More informationAchieving Data Liquidity in the Cancer Community: Proposal for a Coalition of All Stakeholders
Achieving Data Liquidity in the Cancer Community: Proposal for a Coalition of All Stakeholders Marcia A. Kean, Feinstein Kean Healthcare National Cancer Policy Forum Informatics Needs and Challenges in
More information